Male Breast Cancer Withdrawn Phase 1 Trials for Cefotaxime (DB00493)

IndicationStatusPhase
DBCOND0028546 (Male Breast Cancer)Withdrawn1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01219907Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast CancerTreatment